Request Demo
Recent blog posts
Latest Hotspot
8 min read
Aztreonam Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Aztreonam is a Small molecule drug targeting PBPs, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Cefepime hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Cefepime hydrochloride is a Small molecule drug targeting PBPs, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Pegol-Sihematide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Pegol-Sihematide is a Synthetic peptide targeting EPO receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Diflunisal Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Diflunisal is a Small molecule drug targeting COXs, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Ruxoprubart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ruxoprubart is a Monoclonal antibody targeting CFB, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.
Latest Hotspot
8 min read
Beinaglutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Beinaglutide is a Recombinant polypeptide targeting GLP-1R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Ipatasertib Dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ipatasertib Dihydrochloride is a Small molecule drug targeting Akt, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Evobrutinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Evobrutinib is a Small molecule drug targeting BTK, at Discontinued. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.
Latest Hotspot
8 min read
Tafamidis Meglumine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Tafamidis Meglumine is a Small molecule drug targeting TTR, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Bosentan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Bosentan is a Small molecule drug targeting ETA x ETB, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Macitentan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Macitentan is a Small molecule drug targeting ETA x ETB, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Cotadutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Cotadutide: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.